title: Indication of hysteroscopy in tamoxifen treated breast cancer patients.
abstract: The aim of this study was to indicate the patients treated with tamoxifen for breast cancer in which hysteroscopy with biopsy should be considered mandatory. 414 breast cancer patients who underwent hysteroscopy with bioptic evaluation were enrolled in the study. 334 subjects were treated with 20 mg of tamoxifen daily as adjuvant therapy for six up to a hundred months. Of the remaining 80 control patients, which had not received tamoxifen, 30 were in premenopause (Group IA) and 50, in postmenopause (Group IIA). The tamoxifen-treated patients were subdivided in premenopausal (Group IB = 72 patients) and in postmenopausal (Group IIB = 262 patients) groups. All patients were further classified in asymptomatic or symptomatic groups considering whether uterine bleeding was absent or present. The evaluation of the endometrial mucosa was performed by office hysteroscopy. In group IIB patients presenting uterine bleeding, malignant lesions were found in 7.8% of the cases. The incidence of premalignant and malignant lesions in IIB patients treated for longer than 3 years (11.7%) was higher than that observed in IIB patients treated for less than 3 years (1.3%). There was a significant difference in terms of endometrial pathology between Group IIB (32.8%) and Group IIA (8%) (p < 0.001); and between Group IIB (32.8%) and Group IB (13.9%) women (p = 0.003). Among IA and IIA patients there were no cases of endometrial hyperplasia or cancer; on the contrary, in IB and IIB women, 2 and 22 cases of atypical hyperplasia were observed, respectively. All cases of endometrial cancer were observed in Group IIB and had a diagnosis of poor prognosis. In conclusion the hysteroscopy with biopsy should be considered the first diagnostic procedure to perform in tamoxifen-treated postmenopausal patients presenting uterine bleeding and in postmenopausal women treated for longer than 3 years. In premenopause, hysteroscopy should be proposed to women with ultrasonographic abnormalities and/or with uterine bleeding to patients at high risk for endometrial cancer.
authors.affiliation: Dept. of Reproductive Medicine and Child Development, University of Pisa, Italy. FabioTaponeco@hotmail.com
authors.forename: F
authors.initials: F
authors.lastname: Taponeco
authors.forename: C
authors.initials: C
authors.lastname: Curcio
authors.forename: A
authors.initials: A
authors.lastname: Fasciani
authors.forename: A
authors.initials: A
authors.lastname: Giuntini
authors.forename: P G
authors.initials: PG
authors.lastname: Artini
authors.forename: G
authors.initials: G
authors.lastname: Fornaciari
authors.forename: F
authors.initials: F
authors.lastname: Petraglia
authors.forename: A R
authors.initials: AR
authors.lastname: Genazzani
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D001943:Breast Neoplasms / Q000188:drug therapy*; D004714:Endometrial Hyperplasia / Q000139:chemically induced / Q000175:diagnosis*; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000175:diagnosis*; D004717:Endometrium / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015907:Hysteroscopy / Q000379:methods*; D015994:Incidence; D008403:Mass Screening; D008875:Middle Aged; D017698:Postmenopause; D017697:Premenopause; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen